Oryzon Genomics S.A (ORYZF PINK) stock market data APIs
$3.6143
0(0%)
as of October 31, 2025
Try our APIs with
free plan!
Oryzon Genomics S.A Financial Data Overview
Price chart is built with
Anychart
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Prev. Close
3.6143
Open
3.6143
High
3.6143
Low
3.6143
52 wk Range
1.565-4.375
Market Cap
323 M
Shares Outstanding
78 853 K
Revenue
7 471 K
Beta
0.448
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oryzon Genomics S.A data using free add-ons & libraries
Get Oryzon Genomics S.A Fundamental Data
Oryzon Genomics S.A Fundamental data includes:
- Net Revenue: 7 471 K
- EBITDA: -4 915 176
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-22
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oryzon Genomics S.A News
New
High Growth Tech Stocks To Watch In October 2025
Amid a volatile global market landscape, U.S. stocks have recently rebounded following a week of substantial fluctuations, buoyed by easing trade tensions and dovish signals from the Federal Reserve. ...
3 European Growth Companies Insiders Are Heavily Investing In
As European markets navigate a mixed landscape marked by dovish signals from the U.S. Federal Reserve and fluctuating industrial outputs, investors are increasingly focusing on growth companies with s...
European Growth Companies With High Insider Ownership In September 2025
In September 2025, the European markets have been navigating a complex economic landscape, with the pan-European STOXX Europe 600 Index ending slightly lower amid a series of monetary policy decisions...
High Growth Tech Stocks In Europe For September 2025
As European markets navigate a complex landscape of monetary policy decisions, with the pan-European STOXX Europe 600 Index ending the week slightly lower, investors are keenly assessing the impact of...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
